Tamara Khazbieva
Family · Sequim, WANPI 1477225837
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,920 of the $3,559 with a category attached, or 82.0%. It is spread thinly across 41 manufacturers, the largest accounting for just 8.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $25.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$306
- Amgen$274
- Merck$228
- Takeda Pharmaceuticals U.S.A., Inc.$228
- Genentech USA, Inc.$202
- Johnson & Johnson$193
- plus $2K from 35 others
What the payments were for
- Food & beverage$2,92082%
- Education$63918%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $306 |
| Amgen | 9 | $274 |
| Merck | 9 | $228 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $228 |
| Genentech USA, Inc. | 9 | $202 |
| Johnson & Johnson(2 entities) | 5 | $193 |
| Incyte Corporation | 7 | $165 |
| AstraZeneca | 4 | $146 |
| Tempus AI, Inc | 2 | $146 |
| Bristol Myers Squibb | 6 | $130 |
| Astellas Pharma US Inc | 5 | $103 |
| AVEO Pharmaceuticals, Inc. | 3 | $101 |
| Sanofi | 4 | $99 |
| Pfizer | 6 | $96 |
| Seagen Inc. | 1 | $90 |
| Bayer | 4 | $79 |
| Daiichi Sankyo Inc. | 3 | $74 |
| Sobi, Inc | 2 | $65 |
| Eisai Inc. | 3 | $61 |
| Tersera Therapeutics LLC | 2 | $56 |
| GSK | 3 | $55 |
| Exelixis Inc. | 2 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| Morphosys, US Inc. | 3 | $50 |
| Genmab U.S., Inc. | 2 | $49 |
| Blueprint Medicines Corporation | 2 | $42 |
| Lilly USA, LLC | 2 | $42 |
| Ipsen Biopharmaceuticals, Inc | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 1 | $39 |
| Beigene USA, Inc. | 2 | $37 |
| Pharmaessentia USA Corporation | 2 | $36 |
| Array Biopharma Inc | 2 | $33 |
| Emmaus Medical, Inc. | 1 | $32 |
| Taiho Oncology, Inc. | 1 | $26 |
| Geron Corporation | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| G1 Therapeutics, Inc. | 1 | $19 |
| EMD Serono, Inc. | 1 | $17 |
| Immunogen, Inc. | 1 | $16 |
| Servier Pharmaceuticals LLC | 1 | $14 |
How this compares
$3,559 in reported general payments places this provider in the 90th percentile of 1,706 family providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProcritEpoetin Alfa | 14 | $61,540 |
| EliquisApixaban | 41 | $41,678 |
| Hydroxyurea | 23 | $1,530 |
| Anastrozole | 34 | $1,457 |
| Fentanyl | 16 | $1,246 |
| Letrozole | 24 | $1,018 |
| Prochlorperazine Maleate | 70 | $779 |
| Fluconazole | 13 | $679 |
| Acyclovir | 31 | $638 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $551 |
| Dexamethasone | 20 | $535 |
| Pantoprazole Sodium | 18 | $447 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 40 | $443 |
| Oxycodone Hcl | 17 | $423 |
| Ondansetron OdtOndansetron | 34 | $340 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonProcrit | $193 | $61,54014 claims |
| PfizerEliquis | $96 | $41,67841 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,706 family providers in Washington.
Other family in Sequim
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
- Hye-Jin GehringBellevue$30K
- Kaitlin BrasierSeattle$29K
- Karen JohnsonSeattle$16K
- Brittanee WorthySpokane Valley$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.